A New Perspective on Lowering CV Risk From Hypoglycemia A New Perspective on Lowering CV Risk From Hypoglycemia
A new study explores the relationship between hypoglycemia, cardiovascular outcomes, and treatment with an SGLT2 inhibitor. Might an SGLT2 inhibitor offer a cardio-protective effect?European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 12, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

SGLT2 Inhibition: A New Avenue to Protect the Kidney SGLT2 Inhibition: A New Avenue to Protect the Kidney
Could SGLT2 inhibitors have a role in the management of patients with kidney disease? What are the benefits of these agents?Nephrology Dialysis Transplantation (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 12, 2020 Category: Surgery Tags: Nephrology Journal Article Source Type: news

SGLT2 Inhibitors: Searching for Mechanisms SGLT2 Inhibitors: Searching for Mechanisms
Recent trials are exploring the role of SGLT2 inhibitors in cardiovascular disease, highlighting their clinical utility beyond diabetes. But their mechanism of cardiac effects remains unclear.Circulation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 31, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

SGLT2 Inhibitors Risky in Latent Autoimmune Diabetes SGLT2 Inhibitors Risky in Latent Autoimmune Diabetes
Sodium-glucose co-transporter-2 (SGLT2) inhibitors can cause ketoacidosis in patients with latent autoimmune diabetes (LADA), a report on three cases in the American Journal of Medicine confirms.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 22, 2020 Category: Allergy & Immunology Tags: Diabetes & Endocrinology News Source Type: news

Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report - Nakamura M, Nakade J, Toyama T, Okajima M, Taniguchi T.
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors inhibit SGLT2, which is expressed in the proximal renal tubule, and thus reduce blood glucose levels by enabling the urinary excretion of excess glucose. SGLT2 inhibitors have been reported to s... (Source: SafetyLit)
Source: SafetyLit - January 14, 2020 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news

Diabetes Drug Class May Hold Promise for Gout Prevention Diabetes Drug Class May Hold Promise for Gout Prevention
Adults with type 2 diabetes prescribed an SGLT2 inhibitor were less likely to develop gout than those prescribed a GLP-1 receptor agonist.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - January 13, 2020 Category: Primary Care Tags: Diabetes & Endocrinology News Source Type: news

Gout Incidence Down With SGLT2 Inhibitors in Type 2 Diabetes
MONDAY, Jan. 13, 2020 -- Adults with type 2 diabetes newly prescribed a sodium-glucose cotransporter-2 (SGLT2) inhibitor have a lower incidence of gout than those prescribed a glucagon-like peptide-1 (GLP-1) receptor agonist, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 13, 2020 Category: Pharmaceuticals Source Type: news

Certain Diabetes Meds May Lower Gout Risk, Too
MONDAY, Jan. 13, 2020 -- Medications called SGLT2 inhibitors lower blood sugar in people with type 2 diabetes. And new research suggests these drugs may have an added benefit -- lowering the risk of gout. Compared with people taking another class... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 13, 2020 Category: General Medicine Source Type: news

Dapagliflozin Granted Priority Review for Adults With Heart Failure Dapagliflozin Granted Priority Review for Adults With Heart Failure
The application for the SGLT2 inhibitor is based on the results from the landmark phase 3 DAPA-HF trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 8, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

ADA Advises Wider Use of Newer Glucose-Lowering Drugs ADA Advises Wider Use of Newer Glucose-Lowering Drugs
In the 2020 Standards of Care, the American Diabetes Association advises consideration of SGLT2 inhibitors and GLP-1 receptor agonists in patients with high CVD or renal risk, regardless of A1c.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 20, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 inhibitors for diabetes are safe for older adults
According to a new study presented at the International Diabetes Federation (IDF) Congress 2019, SGLT2 inhibitors for the treatment of diabetes are safe and effective for older adults.Medscape (Source: Society for Endocrinology)
Source: Society for Endocrinology - December 20, 2019 Category: Endocrinology Source Type: news

SGLT2 Inhibitors for Diabetes Safe, Effective in Older Adults SGLT2 Inhibitors for Diabetes Safe, Effective in Older Adults
Real-world study suggests that they work just as well in adults aged 65 and older, although the genital-urinary infection rate was high.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 19, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Canagliflozin Helps Heart, Kidneys in'Well-Controlled' Diabetes Canagliflozin Helps Heart, Kidneys in'Well-Controlled' Diabetes
A subanalysis of CREDENCE suggests that SGLT2 inhibitor use should be based on clinical benefit, not solely glycemic control, say researchers. Another study hints that these drugs up EPO levels.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 10, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Highlights From ASN Kidney Week 2019 Highlights From ASN Kidney Week 2019
Highlights from ASN's Kidney Week 2019 include results from the CREDENCE trial showing benefit from the SGLT2 inhibitor canagliflozin for patients with established diabetic nephropathy.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 3, 2019 Category: Consumer Health News Tags: Nephrology ReCAP Source Type: news

DAPA-HF: Dapagliflozin Benefits Regardless of Age, HF Severity DAPA-HF: Dapagliflozin Benefits Regardless of Age, HF Severity
The SGLT2 inhibitor showed about the same effect on its clinical primary end point in the very elderly and across all degrees of symptom status at baseline in two new analyses.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 25, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

DAPA-HF: Heart Failure Toolbox Poised to Add New Drug Family DAPA-HF: Heart Failure Toolbox Poised to Add New Drug Family
' What I don't want to see is slow uptake, once it gets the indication in nondiabetics,'said one physician. Think of SGLT2 inhibitors the same way as ACE inhibitors, beta blockers, and other HF drugs.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 19, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Newer Diabetes Drugs Given to Those Who Need Them Least Newer Diabetes Drugs Given to Those Who Need Them Least
' The challenge we have [is that] SGLT2 inhibitors are currently underprescribed, and when they are prescribed,'they're not given to those patients likely to benefit most, says one expert.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 24, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Diabetes drugs may lower risk of dementia
Diabetes drugs such as SGLT2 inhibitors and metformin, may lower risk of dementia in patients with type 2 diabetes, according to a Danish study published in theEuropean Journal of Endocrinology.Speciality Medical Dialogues (Source: Society for Endocrinology)
Source: Society for Endocrinology - October 23, 2019 Category: Endocrinology Source Type: news

SGLT2 Inhibitors Protect Against Kidney Disease in T2DM
THURSDAY, Oct. 10, 2019 -- A class of diabetes drugs, called sodium-glucose co-transporter-2 (SGLT2) inhibitors, protect against kidney disease in patients with type 2 diabetes, according to a review published online Sept. 5 in The Lancet Diabetes... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 10, 2019 Category: Pharmaceuticals Source Type: news

Sep 27 2019 This Week in Cardiology Sep 27 2019 This Week in Cardiology
Social effects of medicine, SGLT2 inhibitors, CIED infections, equity in cardiology, and post-PCI anti-thrombotic therapy are the topics discussed by Dr John Mandrola in this week ’ s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 27, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news

SGLT2 Inhibitors Linked to Lower Risk for Heart Failure
WEDNESDAY, Sept. 18, 2019 -- Use of sodium glucose cotransporter 2 (SGLT2) inhibitors for type 2 diabetes is associated with a reduced risk for heart failure, but not a reduced risk for major cardiovascular events, compared with use of dipeptidyl... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 20, 2019 Category: Pharmaceuticals Source Type: news

DAPA-HF Published:'Stunning Consistent Benefit With Dapagliflozin'DAPA-HF Published:'Stunning Consistent Benefit With Dapagliflozin '
Publication of trial reinforces"remarkably consistent" benefits of the SGLT2 inhibitor dapagliflozin in patients with heart failure, with or without diabetes,"bolsters confidence in the conclusions."Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

' Strongest Evidence Yet' That Diabetes Drugs Are Renoprotective'Strongest Evidence Yet' That Diabetes Drugs Are Renoprotective
Meta-analysis of four major trials in patients with type 2 diabetes shows significant renal benefit of SGLT2 inhibitors, even in patients with reduced kidney function.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 12, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 inhibitors may help prevent kidney failure
A study published in theLancet Diabetes and Endocrinology has found SGLT2 inhibitors, taken to lower blood glucose levels, prevent loss of kidney function and kidney failure in people with type 2 diabetes.MedicalXpress (Source: Society for Endocrinology)
Source: Society for Endocrinology - September 6, 2019 Category: Endocrinology Source Type: news

Will DAPA-HF Turn the Tide on Heart Failure? Will DAPA-HF Turn the Tide on Heart Failure?
The term gamechanger is overused but may be appropriate for the DAPA-HF trial on the SGLT2 inhibitor dapagliflozin in patients with heart failure and reduced ejection fraction. Medical conservative John Mandrola, MD, was impressed.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 6, 2019 Category: Cardiology Tags: Cardiology Expert Column Source Type: news

SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis
SGLT2 inhibitors are commonly used in the treatment of type 2 diabetes, but might their use also contribute to the potential development of diabetic ketoacidosis?Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 6, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news

Cardiologists Should Prescribe SGLT2 Inhibitors Cardiologists Should Prescribe SGLT2 Inhibitors
Is it fair to expect cardiologists to now prescribe the new diabetes drugs? Presentations at the European Society of Cardiology Congress prove persuasive to Melissa Walton-Shirley, MD.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 5, 2019 Category: Consumer Health News Tags: Cardiology Expert Column Source Type: news

Newer diabetes drug drops heart failure risk by 34 percent, study says
Newer drugs for type 2 diabetes called SGLT2 inhibitors may also have a beneficial side effect for cardiovascular health, with a study showing they can reduce heart failure risk by 34 percent. (Source: Health News - UPI.com)
Source: Health News - UPI.com - August 29, 2019 Category: Consumer Health News Source Type: news

DAPA-HF Top-Line Results: Dapagliflozin Hits Primary Outcome DAPA-HF Top-Line Results: Dapagliflozin Hits Primary Outcome
The SGLT2 inhibitor dapagliflozin provided significant and clinically meaningful reductions in heart failure outcomes, according to the sponsoring company.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 20, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

' Reassuring': New Type 2 Diabetes Drugs Not Linked to UTIs'Reassuring': New Type 2 Diabetes Drugs Not Linked to UTIs
Analyses from 2 large databases find no greater risk for urinary tract infections with one kind of new type 2 diabetes agent, SGLT2 inhibitors, compared with DPP4 inhibitors or GLP1 receptor agonists.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - July 29, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Periop Diabetic Ketoacidosis Seen in Patients on SGLT2 Inhibitors
WEDNESDAY, July 24, 2019 -- Sodium-glucose cotransporter-2 inhibitor (SGLT2i)-associated diabetic ketoacidosis (DKA) may occur after surgery even in patients with normal or near-normal blood glucose levels, according to a review published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 24, 2019 Category: Pharmaceuticals Source Type: news

Fournier Gangrene, Genitourinary Infection With SGLT2i: ADA 2019 Fournier Gangrene, Genitourinary Infection With SGLT2i: ADA 2019
SGLT2 inhibitors carry warnings about Fournier gangrene (a necrotizing fasciitis of the genitalia), genital fungal infections, and UTIs. What new data were presented at the 2019 American Diabetes Association meeting?Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - July 18, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology Article Source Type: news

No Fracture Risk for New Diabetes Drugs in Real-World Study No Fracture Risk for New Diabetes Drugs in Real-World Study
Link between SGLT2 inhibitors for type 2 diabetes and fractures has been controversial. Canagliflozin has an FDA warning about the risk, but some studies have found no link.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - July 17, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

How Do the Renal Data From CREDENCE and CARMELINA Compare? How Do the Renal Data From CREDENCE and CARMELINA Compare?
Meg Jardine and Christoph Wanner, investigators from the CREDENCE and CARMELINA trials, respectively, discuss the implications for SGLT2 inhibitor and DPP-4 inhibitor use in patients with kidney disease.Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 26, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news

Diabetes treatment does not increase risk of bone fracture
According to a recent study inOsteoporosis International, antidiabetic therapies, GLP-1 agonists, SGLT2 inhibitors and DPP-IV inhibitors, do not increase the risk of bone fractures in patients with type 2 diabetes.Healio (Source: Society for Endocrinology)
Source: Society for Endocrinology - June 18, 2019 Category: Endocrinology Source Type: news

CREDENCE'Knocks Your Socks Off'; New Analysis Reported at ADA CREDENCE'Knocks Your Socks Off'; New Analysis Reported at ADA
Latest analysis of CREDENCE with SGLT2 inhibitor canagliflozin shows the agent has a cardio- and renal-protective effect in both primary and secondary CV prevention populations.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - June 17, 2019 Category: Internal Medicine Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitor Reduces CV, Renal Events in Type 2 Diabetes
ADA 2019 —Dapagliflozin reduced CV death, hospitalization for HF, and progression of CKD among T2DM patients with a wide distribution of baselines CVD risk in DECLARE-TIMI 58. (Source: ConsultantLive)
Source: ConsultantLive - June 17, 2019 Category: Internal Medicine Authors: Kenneth Bender, PharmD, MA Tags: Cardiovascular Disease Diabetes Diabetes Type 2 Source Type: news

CREDENCE Shifts Our Thinking About SGLT2 Inhibitors CREDENCE Shifts Our Thinking About SGLT2 Inhibitors
The CREDENCE trial allows us to start thinking of SGLT2 inhibitors as drugs for preserving renal function, independent of other parameters, says Anne Peters.Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - June 14, 2019 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news

More DECLARE-TIMI: Robust Renal Effects of Dapagliflozin More DECLARE-TIMI: Robust Renal Effects of Dapagliflozin
A new analysis from the landmark trial with the diabetes drug dapagliflozin shows a large, robust effect on important kidney outcomes. Accumulating data support'leading role for SGLT2 inhibitors,'in diabetes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 11, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Fournier Gangrene Is Safety Concern With SGLT2 Inhibitors
MONDAY, May 13, 2019 -- Fournier gangrene (FG) is a safety concern for adults with diabetes receiving treatment with sodium-glucose cotransporter-2 (SGLT2) inhibitors, according to a study published online May 7 in the Annals of Internal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 13, 2019 Category: Pharmaceuticals Source Type: news

Study warns of flesh-eating genital infection linked to diabetes drugs
A new study echoes a previous FDA warning about the link between Type 2 diabetes drugs known as SGLT2 inhibitors and the genital infection called Fournier gangrene. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 10, 2019 Category: Pharmaceuticals Source Type: news

SGLT2, Fournier Gangrene Link Is'Compelling'--What to Do? SGLT2, Fournier Gangrene Link Is'Compelling'--What to Do?
Fournier gangrene is an uncommon but unignorable adverse event associated with SGLT2 inhibitors. What does this mean for clinical practice?Medscape (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - May 8, 2019 Category: Internal Medicine Tags: Internal Medicine Commentary Source Type: news

Diabetes Drugs Carry Risk of Gangrene of Genitals
Popular diabetes drugs known as SGLT2 inhibitors are linked with an increased risk of developing a flesh-eating bacteria that attacks the genitals, a rare condition known as Fournier gangrene. (Source: WebMD Health)
Source: WebMD Health - May 8, 2019 Category: Consumer Health News Source Type: news

Fournier Gangrene Alarm: More Cases Linked to Diabetes Drugs Fournier Gangrene Alarm: More Cases Linked to Diabetes Drugs
Physicians prescribing SGLT2 inhibitors, a newer class of diabetes drugs, are advised to"have a high index of suspicion" about the potentially fatal complication.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 6, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

SGLT2 Inhibitors for Diabetes Linked to Rare'Flesh-Eating' Genital Infection
MONDAY, May 6, 2019 -- Say you have type 2 diabetes and you are taking a newer class of medications to treat your disease -- but one day you notice pain, redness and a foul odor in your genital area. If this happens, new research suggests you need... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 6, 2019 Category: General Medicine Source Type: news

Novel therapies slow CKD progression in patients with diabetes
(ERA-EDTA) The recently published CREDENCE study showed that SGLT2 inhibitors can slow progression of chronic kidney disease (CKD) in diabetes patients in addition to the effects seen with RAAS blockade. Canagliflozin was associated with a 34% risk reduction of the renal end point. The SONAR study had shown that the selective endothelin A receptor antagonist, atrasentan, reduced the risk of renal events in a specially selected CKD cohort with diabetes to a similar extent (35%). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 26, 2019 Category: International Medicine & Public Health Source Type: news

CREDENCE Takes SGLT2 Inhibitors'to the Next Level'CREDENCE Takes SGLT2 Inhibitors'to the Next Level '
What are the clinical implications of the CREDENCE trial? Dr Harpreet Bajaj shares his perspective on this landmark study.Medscape Diabetes & Endocrinology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 25, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology Expert Column Source Type: news

Less HF Hospitalization on Dapagliflozin in Diabetes at Any LVEF Less HF Hospitalization on Dapagliflozin in Diabetes at Any LVEF
Survivals gains were seen in DECLARE-TIMI 58 only in those with low ejection fractions. Preliminary, but it suggests an SGLT2 inhibitor benefit in a range of people with diabetes and heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 4, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Diabetes and Kidney Complications Garnering Attention at ISN Diabetes and Kidney Complications Garnering Attention at ISN
First results indicating that an SGLT2 inhibitor could improve outcomes for patients with diabetes and chronic kidney disease will be presented at the upcoming nephrology world congress.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 26, 2019 Category: Consumer Health News Tags: Nephrology News Source Type: news

Low EF Heart Failure Benefits Most From SGLT2 Diabetes Drug
(MedPage Today) -- DECLARE substudy doesn't leave HFpEF entirely out, though (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 20, 2019 Category: Cardiology Source Type: news